Review
doi: 10.1016/j.hfc.2014.04.005.
Novel biomarkers in heart failure with preserved ejection fraction
Affiliations
- PMID: 24975910
- DOI: 10.1016/j.hfc.2014.04.005
Item in Clipboard
Review
Novel biomarkers in heart failure with preserved ejection fraction
Heart Fail Clin.
2014 Jul.
Abstract
Heart failure with preserved ejection fraction (HFPEF) is a common subtype of heart failure with morbidity and mortality similar to that of heart failure with systolic dysfunction. This article discusses the numerous biomarkers that promise to play a substantial role in terms of our ability to understand the mechanisms of HFPEF and discern possible phenotypes that respond to targeted therapies: natriuretic peptides, high-sensitivity troponins, galectin-3, soluble ST2, neutrophil gelatinase-associated lipocalin, and cystatin C.
Keywords: Biomarkers; Diagnosis; Heart failure; Preserved ejection fraction; Prognosis.
Published by Elsevier Inc.
Similar articles
-
Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.Eur J Heart Fail. 2012 Dec;14(12):1338-47. doi: 10.1093/eurjhf/hfs130. Epub 2012 Aug 5. Eur J Heart Fail. 2012. PMID: 22869458
-
Clinical Application of Biomarkers in Heart Failure with a Preserved Ejection Fraction: A Review.Cardiology. 2017;136(3):192-203. doi: 10.1159/000450573. Epub 2016 Oct 27. Cardiology. 2017. PMID: 27784010 Review.
-
Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction.Int J Cardiol. 2014;172(1):e250-2. doi: 10.1016/j.ijcard.2013.12.101. Epub 2014 Jan 4. Int J Cardiol. 2014. PMID: 24467978 No abstract available.
-
Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.J Am Coll Cardiol. 2014 Jan 21;63(2):158-66. doi: 10.1016/j.jacc.2013.07.087. Epub 2013 Sep 24. J Am Coll Cardiol. 2014. PMID: 24076531
-
Can biomarkers help to diagnose early heart failure with preserved ejection fraction?Dis Markers. 2015;2015:426045. doi: 10.1155/2015/426045. Epub 2015 Jan 31. Dis Markers. 2015. PMID: 25802475 Free PMC article. Review.
Cited by
-
Differentiating pulmonary transfusion reactions using recipient and transfusion factors.Transfusion. 2017 Jul;57(7):1684-1690. doi: 10.1111/trf.14118. Epub 2017 May 3. Transfusion. 2017. PMID: 28470756 Free PMC article.
-
Rehabilitation Enablement in Chronic Heart Failure-a facilitated self-care rehabilitation intervention in patients with heart failure with preserved ejection fraction (REACH-HFpEF) and their caregivers: rationale and protocol for a single-centre pilot randomised controlled trial.BMJ Open. 2016 Oct 25;6(10):e012853. doi: 10.1136/bmjopen-2016-012853. BMJ Open. 2016. PMID: 27798024 Free PMC article. Clinical Trial.
-
Biomarkers in heart failure: the past, current and future.Heart Fail Rev. 2019 Nov;24(6):867-903. doi: 10.1007/s10741-019-09807-z. Heart Fail Rev. 2019. PMID: 31183637 Review.
-
Prognostication in Different Heart Failure Phenotypes: The Role of Circulating Biomarkers.J Circ Biomark. 2016 Mar 16;5:6. doi: 10.5772/62797. eCollection 2016 Jan-Dec. J Circ Biomark. 2016. PMID: 28936254 Free PMC article. Review.
-
Thymosin Beta-4 Is Elevated in Women With Heart Failure With Preserved Ejection Fraction.J Am Heart Assoc. 2017 Jun 13;6(6):e005586. doi: 10.1161/JAHA.117.005586. J Am Heart Assoc. 2017. PMID: 28611096 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
